Amicus Therapeutics Files 8-K on Financial Condition

Ticker: FOLD · Form: 8-K · Filed: Feb 28, 2024 · CIK: 1178879

Amicus Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyAmicus Therapeutics, Inc. (FOLD)
Form Type8-K
Filed DateFeb 28, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: financial-condition, 8-K, corporate-filing

TL;DR

**Amicus Therapeutics just dropped an 8-K on its financials, giving investors a peek into its latest performance.**

AI Summary

Amicus Therapeutics, Inc. filed an 8-K on February 28, 2024, reporting on its results of operations and financial condition. The filing indicates the company's principal executive offices are located at 47 Hulfish Street, Princeton, NJ 08542, with a business phone number of 609-662-2000. This current report was filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Why It Matters

This filing provides an update on Amicus Therapeutics' financial health and operational performance, which can influence investor decisions and market perception of the company's stability and future prospects.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial condition and operations, not indicating any immediate adverse events.

Key Players & Entities

  • AMICUS THERAPEUTICS, INC. (company) — Registrant
  • February 28, 2024 (date) — Date of earliest event reported
  • 47 Hulfish Street , Princeton , NJ 08542 (location) — Address of Principal Executive Offices
  • 609-662-2000 (dollar_amount) — Registrant’s Telephone Number
  • Delaware (location) — State of Incorporation

FAQ

What was the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported was February 28, 2024.

What is the exact name of the registrant as specified in its charter?

The exact name of the registrant is AMICUS THERAPEUTICS, INC.

Where are Amicus Therapeutics, Inc.'s principal executive offices located?

The principal executive offices are located at 47 Hulfish Street, Princeton, NJ 08542.

What is the registrant's telephone number?

The registrant's telephone number is 609-662-2000.

Under which sections of the Securities Exchange Act of 1934 was this report filed?

This report was filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Filing Stats: 557 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-02-28 07:02:29

Key Financial Figures

  • $0.01 — ich registered Common Stock Par Value $0.01 FOLD Nasdaq Indicate by check mar

Filing Documents

02 – Results of Operations and Financial

Item 2.02 – Results of Operations and Financial Condition On February 28, 2024, Amicus Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the fiscal year ended December 31, 2023. A copy of this press release is attached hereto as Exhibit 99.1. The Company will host a conference call and webcast on February 28, 2024 to discuss its full year results of operations. A copy of the conference call presentation materials is attached hereto as Exhibit 99.2. Both exhibits are incorporated herein by reference. In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K and the Exhibits shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits: Exhibit No. Description 99.1 Press Release, dated February 28, 2024 99.2 February 28, 2024 Conference Call Presentation Materials 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Signature Page Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AMICUS THERAPEUTICS, INC. Date: February 28, 2024 By: /s/ Ellen S. Rosenberg Name: Ellen S. Rosenberg Title: Chief Legal Officer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.